(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
David V Goeddel, 10% Owner, Director, on June 09, 2022, executed a purchase for 984,161 shares in Ngm Biopharmaceuticals (NGM) for $13,286,174. Following...
David V Goeddel, 10% Owner, Director, on June 02, 2022, executed a purchase for 34,200 shares in Ngm Biopharmaceuticals (NGM) for $445,739. Following the...
David V Goeddel, 10% Owner, Director, on May 31, 2022, executed a purchase for 153,806 shares in Ngm Biopharmaceuticals (NGM) for $2,069,667. Following the...
| Address | 333 Oyster Point Boulevard South San Francisco, California 94080-7014 |
| Phone | +1.650.243.5555 |
| Number of Employees | N/A |
| Recent SEC Filing | 08/04/2022 8-K |
| Chief Executive Officer & Director | David J. Woodhouse |
| President & Chief Financial Officer | Siobhan Nolan Mangini |
| Director & Chief Scientific Officer | Jin Long Chen |
| Vice President-Research | Hui Tian |
| Price Open | $16.06 |
| Previous Close | $16.24 |
| 52 Week Range | $10.49 - 27.25 |
| Market Capitalization | $1.4 B |
| Shares Outstanding | 80.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.73 |
| Beta vs. S&P 500 | N/A |
| Revenue | $108.7 M |
| Net Profit Margin | -196.39% |
| Return on Equity | -41.79% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
